ClinicalTrials.Veeva

Menu

PEL-1235_REN-0176-I (Pelicon)

T

Technical University of Munich

Status

Completed

Conditions

Immunosuppression After Kidney Transplantation

Treatments

Other: tacrolimus Prograf
Other: tacrolimus Advagraf

Study type

Observational

Funder types

Other

Identifiers

NCT01904045
PEL-1235_REN-0176-I

Details and patient eligibility

About

Aim of this study is to investigate whether in patients following kidney transplantation (>6 months after transplantation), the intra-patient variability of levels of tacrolimus is comparable after administration of tacrolimus twice daily (Prograf) to tacrolimus once daily (Advagraf), with each regimen for 3 months.

Enrollment

51 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • signed written informed consent
  • male or female patient ≥ 18years of age
  • Patient has received a kidney transplantation at least 6 months prior to inclusion into the study
  • No acute rejection episodes for at least 3 months
  • PRG through level and dosing stable for at least 1 month
  • Patient is capable of understanding the purpose and risks of the study, has been fully informed and has given written informed consent to participate in the study

Exclusion criteria

  • Acute rejection episodes within the last 3 months prior to study entry
  • Unstable PRG trough level or dose change in the month before study entry
  • History of noncompliance to medical regimens
  • Patients unwilling to or unable to comply with the protocol
  • Treatment with another investigational product during this study or during the last 30 days prior to study start

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems